A Study of Vonapanitase (PRT-201) Administered Immediately After Radiocephalic Arteriovenous Fistula(AVF) Creation in Patients With Chronic Kidney Disease (CKD) (PATENCY-2)

Completed · Phase 3 · Has a placebo group

Conditions studied: Chronic Kidney Disease

In brief

This research study is designed to assess the safety and effectiveness of an experimental drug called vonapanitase (PRT-201) in patients both receiving or expecting to receive hemodialysis who have chronic kidney disease and who are undergoing surgery to create a new access point to their bloodstream for hemodialysis. Vonapanitase is a protein that has been shown in previous research studies to help keep vessels patent when applied to the outside surface of the blood vessels (arteries and veins) in patients who undergo surgery to create an arteriovenous fistula (AVF). The purpose of this study is to determine whether vonapanitase when applied to a limited segment of your blood vessel (about 2 inches) immediately after surgery is safe and improves the patency of your AVF.

Key facts

Study ID

NCT02414841

Run by

Proteon Therapeutics

People needed

696

Starts

2015-08-01

Expected to finish

2019-05-01

Last updated by the study team

2019-08-13

Who can join

Age: 18 and older, up to 100. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age of at least 18 years.
• Life expectancy of at least 6 months.
• Diagnosis of CKD.
• Planned creation of a new radiocephalic AVF (revision of an existing AVF is not eligible).
• Ability to understand and comply with the requirements of the entire study and to communicate with the study team.
• Written informed consent using a document that has been approved by the Institutional Review Board (IRB) or Independent Ethics Committee (IEC).
• If female and of childbearing potential (premenopausal and not surgically sterile) must have a negative serum pregnancy test at the screening visit and be willing to use contraception from the time of the screening visit to 2 weeks following study drug administration. Acceptable methods of birth control include abstinence, barrier methods, hormones, or intra-uterine device.

You may not qualify if…

• Malignancy or treatment for malignancy within the previous 12 months with the exception of the following cancers if they have been resected: localized basal cell or squamous cell skin cancer, or any cancer in situ.
• Presence of any significant medical condition that might significantly confound the collection of safety and efficacy data in this study.
• Previous treatment with vonapanitase (PRT-201).
• Treatment with any investigational drug within the previous 30 days or investigational antibody therapy within the previous 90 days prior to signing informed consent.

Where it is running

• University of Alabama at Birmingham — Birmingham, Alabama, United States
• AKDHC Medical Research Services, LLC — Phoenix, Arizona, United States
• Banner University Medical Center Tucson — Tucson, Arizona, United States
• AKDHC Medical Research Services, LLc — Tucson, Arizona, United States
• VA Loma Linda Healthcare System — Loma Linda, California, United States
• VA Medical Center Long Beach — Long Beach, California, United States
• Keck University Hospital at USC — Los Angeles, California, United States
• Kaiser Permanente — San Diego, California, United States
• California Institute of Renal Research — San Diego, California, United States
• Kaiser Permanente Northern California — San Francisco, California, United States
• University of Chicago — Chicago, Illinois, United States
• RenalCare Associates, S.C. — Peoria, Illinois, United States
• Lutheran Hospital Network of Indiana — Fort Wayne, Indiana, United States
• The University of Iowa Hospitals and Clinics — Iowa City, Iowa, United States
• University of Louisville — Louisville, Kentucky, United States
• Tulane University — New Orleans, Louisiana, United States
• Maine Medical Center — Portland, Maine, United States
• Brigham and Women's Hospital — Boston, Massachusetts, United States
• University of Massachusetts Medical Center — Worcester, Massachusetts, United States
• VA Ann Arbor Healthcare System — Ann Arbor, Michigan, United States
• Henry Ford Hospital — Detroit, Michigan, United States
• Greenwood Leflore Hospital — Greenwood, Mississippi, United States
• Saint Luke's Hospital — Kansas City, Missouri, United States
• New York Presbyterian Hospital-Weill Cornell Medical Center — New York, New York, United States
• University of North Carolina at Chapel Hill — Chapel Hill, North Carolina, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.